LSI

Hot off the press! The latest edition of The Memo, featuring Alex Jiao, Co-Founder & CEO of Scout is out now! Under the direction of Co-Founder and CEO Alex Jiao, Scout is pioneering a transformative approach to home diagnostics, offering rapid, accurate, and affordable tests for a variety of conditions. By merging innovative chemistry with accessible technology, the company aims to redefine how people manage their health—starting in the comfort of their homes. 𝐎𝐫𝐢𝐠𝐢𝐧 𝐒𝐭𝐨𝐫𝐲 The journey of Scout began with a friendship and a shared passion for innovation. Alex Jiao and Cam Ball, Scout’s Co-Founder, met in 2010 as PhD students in bioengineering at the University of Washington. Although their research paths differed, their shared interest in advancing healthcare solutions kept them connected. After years of professional growth—including Jiao founding and selling his own biotech startup—Ball reached out in 2019 with an exciting proposition. “Cam had developed a low-cost, at-home diagnostic technology and was initially focused on STI testing,” Jiao recalled. “As a founder, I was excited to join Cam and help someone start a company.” When the COVID-19 pandemic hit, Scout pivoted to address the immediate global need for at-home testing. This adaptation accelerated their progress and opened the door to broader applications for their platform. 𝐈𝐧𝐬𝐢𝐝𝐞 𝐓𝐡𝐞 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 Scout’s platform is built around a small, user-friendly diagnostic device paired with disposable test kits and a mobile app. The device uses a patented chemistry developed by Ball, simplifying the testing process while reducing costs. Unlike traditional cartridge-based systems, Scout’s test kits contain a single-use test tube containing a proprietary reagent pellet. Continue Reading: https://lnkd.in/guAythnn

With four major acquisitions, Boston Scientific's is powering up their portfolio through strategic M&A 📈 This week's edition of The Numbers — our weekly, no-fluff series with market data and insights from LSI's trusted Market Intelligence team, every Saturday — breaks down Boston Scientific's M&A activity and what we learned in the past year. We explore how their portfolio-augmentation strategy differs from what Johnson & Johnson has done, put their four major deals into context with market data and analysis from Market Intelligence, by LSI, and revisit insights from Michael J. Ryan, Colin Morrison, and Duke Rohlen which clarify the recent activity. Subscribe to The Numbers here on LinkedIn for weekly market intelligence, and tell us what topics you'd like us to tackle next. Axonics, Inc. | Silk Road Medical, Inc. | Relievant Medsystems, Inc. | Cortex Ajax Health PS - looking to connect directly with Boston Scientific's top Venture and Corporate/Business Development executives? They will be at LSI USA '25 on March 17-21. Secure your spot today while space is available: https://lnkd.in/dw_teTUK

As most of us loaded our plates with turkey, the LSI Alumni were loading theirs with new milestones🍗 This week the #LSIAlumni raised $87M, appointed new executives, announced new partnerships, and much more on the road to LSI USA ‘25. Your 60-second news recap: ARC Medical Inc. — Chris Springate → Completed its latest round of funding, raising $3M. → The new funds will support two new clinical trials to further demonstrate the safety and efficacy of its surgical adhesion prevention devices, JOCOAT and IPCOAT liquid medical devices. Distalmotion — Greg Roche → Appointed Sarah Moore as its Chief Marketing Officer. → Distalmotion developed Dexter, a modular, small-format, open-system surgical robot designed to make robotics accessible to more patients. GI Windows Surgical — Brian Tinkham → Secured $37M in Series B funding to accelerate the clinical development and commercialization of its Flexagon self-forming magnet. → The device is designed to provide sutureless end-to-end anastomosis via magnetic compression. Inovus Medical — Elliot Street → Appointed Minogue Medical as its exclusive distribution partner for the Canadian market. → This partnership will support the expansion of Inovus’ surgical simulation training solutions in Canada. LAUXERA CAPITAL PARTNERS — Samuel Levy, Charles Cornevin → Announced the acquisition of LSI Alumni Galen Data. → By leveraging Lauxera’s global reach and expertise, Galen Data aims to accelerate the growth of its compliant medical device connectivity infrastructure into new markets and expand its services. Navigation Sciences — Alan Lucas → Was granted a key patent by the European Patent Office. → The patent covers the company’s NaviSci System for the minimally invasive precision localization and resection of lung and other cancers with real-time surgical margin control. Vitara Biomedical → Successfully closed a $50M Series B funding round to advance its efforts as it progresses toward a first-in-human clinical study. → The company also appointed Kim Rodriguez as its new Chief Executive Officer. Congratulations to all the LSI Alumni who made major news this week!

We have a stellar presenter lineup taking shape for LSI Asia ‘25. Today we’re introducing the first wave of global innovators selected to present in Singapore June 10-13. Here's a sneak peek at the global innovators confirmed to join us in Singapore: • Dr Lynne Lim — Nousq Pte Ltd • Alex Jiao — Scout • Bora Chang, MD — KēlaHealth • Jenny Hoffmann, PhD — Biorithm • Shieak Tzeng — Wellumio • James Lancaster — Solenic Medical Inc. • Caitlin Morse — BrainSpace • Malcolm Hebblewhite — Atmo Biosciences • Lloyd Mencinger — AQUA Medical Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are open. Secure your spot today on our website, or get in touch with our team to learn more.

The momentum continues to build for LSI Asia '25 as we introduce the first wave of global investors and strategics confirmed to join us in Singapore June 10-13. Here's a sneak peek at the global investors & strategics confirmed to join us in Singapore: • Andrew Pieprzyk — Hologic, Inc. • Chris Eso — Medtronic • Dan Lippis — Edwards Lifesciences • C David Adair MD, MBA, FACOG, FASH, C-EFM — Solas BioVentures • William Dai — ShangBay Capital • Dennis McWilliams — SANTÉ Ventures • Michael Wang — Sunmed Capital • Amir Soltanianzadeh — Solardis Health Ventures • Steven M. Gottlieb, M.D. — The Gottlieb Family Office Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are open. Secure your spot today on our website, or get in touch with our team to learn more.

Prescriby (LSI USA '25 Innovator) is an evidence-informed solution designed to enhance the safe prescribing of addictive medications. By addressing a critical gap in healthcare, Prescriby empowers providers to prevent addiction while streamlining workflows and saving valuable time. Best practice guidelines recommend that patients prescribed addictive medications receive education, close monitoring, and a tailored treatment plan to mitigate the risk of addiction. Yet, many healthcare professionals lack the time and tools to consistently meet these standards. Prescriby bridges this gap with its innovative platform. Prescriby has achieved many major milestones recently including: • The company is running pilot projects on opioid and benzodiazepine tapering in Canada and Iceland, with plans underway to establish a pilot in the U.S. • In Q2 2024, Prescriby secured a €2 million pre-seed round led by Crowberry Capital. This funding focuses on scaling operations in Canada and building momentum in the U.S. market as a clinical decision support tool. • Beyond the current pilots, two additional projects are slated for Q1 2025, including a 540-patient clinical trial in Denmark. • In Q3 2024, Prescriby was officially included in the Icelandic Directorate of Health's (Embætti Landlæknis) clinical guidelines for the safe prescribing of addictive medications. We’re excited to announce that Kjartan Thorsson has been selected to present Prescriby at LSI USA ‘25 March 17-21, 2025. Join us in Dana Point to meet with Kjartan and learn more about Prescriby.

What is the role of the CEO versus the board member, chair, or executive chair when making a first-time pitch to an investor, and how is that dynamic perceived? In this clip, the panel outlines the roles of the CEO and board members. They emphasized the importance of the CEO leading their investor pitches to showcase their ability to tell the company’s story and understanding of the business. When board members become too involved in the pitch it can signal a lack of confidence in the CEO’s abilities, potentially undermining their position. To hear more from this incredible group of panelists tune into the full LSI Europe ‘24 panel "Light at the End of the Tunnel in Medtech Financing”, on our website and YouTube channel featuring: • Nick Pachuda (Moderator) — Precision Life Science Partners • Martin Omid A. — Anthro Ventures • Anita Watkins — Rex Health Ventures • Sean Morris — Cultivation Capital • Eman Namati — SpectraWAVE, Inc. - Want to attend our next event? LSI USA ‘25 will be held March 17th-21st in Dana Point, California. Apply today on our website.

With today’s more stringent investor requirements in mind, it’s worth taking a look at a few of the stand-out Medtech investment deals completed thus far in 2024 to help identify common threads attracting investor interest. 𝐖𝐨𝐦𝐞𝐧’𝐬 𝐇𝐞𝐚𝐥𝐭𝐡, 𝐍𝐞𝐮𝐫𝐨𝐬𝐭𝐢𝐦, 𝐚𝐧𝐝 𝐈𝐧𝐜𝐨𝐧𝐭𝐢𝐧𝐞𝐧𝐜𝐞 𝐆𝐚𝐢𝐧 𝐄𝐚𝐫𝐥𝐲-𝐒𝐭𝐚𝐠𝐞 𝐃𝐨𝐥𝐥𝐚𝐫𝐬 Of the early-stage Medtech rounds completed in the first half of the year, UK-based Amber Therapeutics’ huge $100 million Series A haul, which closed in June, tops the list. The company garnered one of the largest Series A rounds ever for a European Medtech company. Although the deal seems massive for a little-known company founded only three years ago, it should not be surprising given Amber’s focus on neuromodulation (one of the hottest growth areas) and women’s health (one of the most underserved), as well as its quick, cash-sparing path to the clinic (the company was founded in 2021, began its first human study in late 2022, and by early 2024 had preliminary results confirming the safety and feasibility of its technology). The Series A raise was financed by a syndicate of US and UK investors led by…. Continue reading this article and explore the full first edition of The Lens for free on our site. Subscribe today to receive the upcoming December issue and all 12 editions in 2025: https://lnkd.in/dZEXphUB

"LSI events are truly transformative for a young Medtech founder. The intimate, selective environment fosters organic connections, where every casual encounter, lunch break, and passing comment turns into pages of valuable notes. Set against a stunning backdrop, under the gentle sun, and within medieval monasteries, there’s no way I can call it a 'conference.' Every moment felt inspiring and productive, and I’m already looking forward to coming back." - Jeyla Sadikova, Co-Founder & CSO of illumicell AI Watch Jeyla and Michel Bielecki MD MPH’s LSI Europe ‘24 presentation to learn more about illumicell AI - available on our website and YouTube channel. - Want to join us in 2025? Our 2025 event schedule is now set with three events across the globe: • LSI USA '25: March 17th – 21st (Dana Point, CA) • LSI Asia '25: June 10th – 13th (Singapore) • LSI Europe '25: September 7th – 11th (London) Visit our website or connect with our team to secure your spot at the best rate for any of our 2025 events.

Recode Ventures (LSI USA ‘25 Investor) is a specialized venture capital firm focused on investing in healthcare AI companies. Established in 2022, with offices in San Francisco and London, Recode partners with visionary founders who believe in the transformative potential of artificial intelligence and emerging technologies to revolutionize healthcare, tackling diseases that affect billions worldwide. Recode invests primarily in Seed and Series A companies, providing not just capital but also a robust support network. The team comprises seasoned investors and operators with extensive experience in research, drug development, product development, healthcare commercialization, market access, regulation, policy, and technology. Recode’s comprehensive approach is why it has become the chosen home for some of the most promising founders who are on a journey to reshape the future through the convergence of healthcare and technology. Recode Ventures' portfolio spans the United States and Europe and includes companies like: • Proprio (LSI Alumni - Gabriel Jones) • LabGenius (James Field) • Sensible Biotechnologies (Miroslav Gasparek) • Nanograb (YC S23) (Debesh Mandal) • among others We’re excited to welcome Vishal Gulati, MD, Founder & Managing Partner, and Armen Vidian, Founder & Managing Partner of Recode Ventures to LSI USA ‘25 this March 17-21 in Dana Point, California. Want to see what other investors are joining us at LSI USA ‘25? Head over to our website to see a preview.